CAMBRIDGE, Mass., June 14, 2017 /PRNewswire/ -- Infinity
Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage
biotechnology company developing IPI-549, a potentially
first-in-class immuno-oncology product candidate that selectively
inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today
announced that management will be participating in the following
three upcoming conferences:
- JMP Securities Annual Life Sciences Conference: Infinity
will participate in the JMP Securities Annual Life Sciences
Conference taking place June 20-21,
2017, in New York City.
Management will host one-on-one meetings on Tuesday, June 20. Additionally, Adelene Perkins, Infinity's chief executive
officer, will join other biotechnology executives in a company
panel presentation entitled "Immuno-Oncology: Novel Approaches"
taking place Wednesday, June 21, from
10:00 a.m. – 11:00 a.m. ET. Topics of discussion are expected
to include next-generation immuno-oncology therapeutics and the
future of combination therapy.
- 2017 Biotechnology Innovation Organization (BIO)
International Convention: Infinity will also participate in the
2017 BIO International Convention taking place June 19-22, 2017, in San Diego, CA. Infinity's president,
Larry Bloch, M.D., J.D., will join
other industry leaders in an educational supersession entitled "The
Scientific American WorldView Super Session: Wrapping Up and
Looking Forward," taking place on Thursday,
June 22, from 1:00 p.m. –
2:15 p.m. PT. The panel will discuss the topics explored
during the convention and provide their views on future trends in
the industry.
- Precision Lung Cancer: Jeffery
Kutok, M.D., Ph.D., chief scientific officer at Infinity,
will discuss the preclinical rationale for targeting PI3K-gamma
previously reported in two publications in
Nature1,2 and summarize previously reported
clinical data from the Phase 1 study of IPI-549 in patients with
advanced solid tumors during the 2017 Precision: Lung Cancer
Conference being held July 25-26,
2017, in Boston, MA. Dr.
Kutok's talk, entitled "Reprogramming Tumor-Associated Macrophages
by Targeting PI3K-Gamma with IPI-549" will take place on
Tuesday, July 25, from 10:00 a.m. – 10:30 a.m.
ET.
IPI-549 has demonstrated activity in preclinical models of lung
cancer, and the expansion phase of the ongoing Phase 1 study of
IPI-549 will include an evaluation of IPI-549 in combination with
Opdivo® (nivolumab), a PD-1 immune checkpoint inhibitor,
in patients with non-small cell lung cancer. IPI-549 is believed to
be the only selective PI3K-gamma inhibitor in clinical
development.
These presentations will not be webcast.
About IPI-549 and the Ongoing Phase 1 Study
IPI-549
is an investigational, orally administered immuno-oncology
development candidate that selectively inhibits PI3K-gamma. In
preclinical studies, IPI-549 reprograms macrophages from a
pro-tumor to an anti-tumor phenotype and is able to overcome
resistance to checkpoint inhibition.1,2 As such, IPI-549
may have the potential to treat a broad range of solid tumors and
represents a potentially complementary approach to restoring
anti-tumor immunity in combination with other immunotherapies such
as checkpoint inhibitors.
A Phase 1 study of IPI-549 in patients with advanced solid
tumors is ongoing to explore the activity, safety, tolerability,
pharmacokinetics and pharmacodynamics of IPI-549 as a monotherapy
and in combination with Opdivo® (nivolumab), a PD-1
immune checkpoint inhibitor, in patients with advanced solid
tumors.3 The study includes monotherapy and combination
dose-escalation phases, in addition to a monotherapy expansion
cohort and combination expansion cohorts. The expansion cohorts
evaluating IPI-549 plus Opdivo will include patients with non-small
cell lung cancer (NSCLC), melanoma and squamous cell carcinoma of
the head and neck (SCCHN). Patients enrolled in these combination
expansion cohorts represent a difficult-to-treat population, as
they must have demonstrated initial resistance or subsequently
develop resistance to a PD-1 or PD-L1 therapy immediately prior to
enrolling in the study. Overall, the study is expected to enroll
approximately 175 patients.
IPI-549 is an investigational compound and its safety and
efficacy has not been evaluated by the U.S. Food and Drug
Administration or any other health authority.
About Infinity
Infinity is an innovative
biopharmaceutical company dedicated to advancing novel medicines
for people with cancer. Infinity is advancing IPI-549, an oral
immuno-oncology development candidate that selectively inhibits
PI3K-gamma. A Phase 1 study in patients with advanced solid tumors
is ongoing. For more information on Infinity, please refer to
Infinity's website at www.infi.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
regarding: the therapeutic potential of PI3K-gamma selective
inhibition and IPI-549, alone and in combination with checkpoint
inhibitors, including Opdivo; clinical trial plans regarding
IPI-549; plans to participate in conferences; and the company's
ability to execute on its strategic plans. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from the
company's current expectations. For example, there can be no
guarantee that IPI-549 will successfully complete necessary
preclinical and clinical development phases. Further, there can be
no guarantee that any positive developments in Infinity's product
portfolio or other strategic options Infinity may pursue will
result in stock price appreciation. Management's expectations and,
therefore, any forward-looking statements in this press release
could also be affected by risks and uncertainties relating to a
number of other factors, including those described in greater
detail under the caption "Risk Factors" included in Infinity's
quarterly report on Form 10-Q filed with the Securities and
Exchange Commission (SEC) on May 9, 2017, and other filings
filed by Infinity with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Infinity expressly disclaims any obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
OPDIVO® is a registered trademark of Bristol-Myers
Squibb.
1 Kaneda, M., Messer, K., Ralainirina, N., Li, H., et
al. PI3Kγ is a molecular switch that controls immune suppression.
Nature, 2016 Nov;539:437–442.
2 De Henau, O., Rausch, M., Winkler, D., Campesato, L.,
et al. Overcoming resistance to checkpoint blockade therapy by
targeting PI3Kγ in myeloid cells. Nature, 2016
Nov;539:443-447.
3 www.clinicaltrials.gov, NCT02637531.
Contact: Jaren Madden,
617-453-1336
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/infinity-to-participate-in-three-upcoming-conferences-300473521.html
SOURCE Infinity Pharmaceuticals, Inc.